The cumulative incidence of HCC development for the group with AFP level < 10.5 ng/mL at the start of DAA therapy was significantly lower than that for the group with AFP level ≥ 10.5 ng/mL (log-rank test p < 0.001). The gene discussed is AFP; the disease is hepatocellular carcinoma.